Novai — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Novai is a private, clinical-stage UK MedTech company developing a novel diagnostic and biomarker platform called DARC. The technology detects apoptosing retinal cells in vivo, providing an early, objective measure of disease activity for conditions like glaucoma and age-related macular degeneration (AMD). Founded and led by renowned clinician-scientist Prof. Francesca Cordeiro, the company is positioning DARC as a tool to empower earlier patient intervention, guide clinician treatment decisions, and de-risk drug development for pharmaceutical partners. Novai appears to be in a pre-revenue, late-stage development phase, advancing its technology through clinical studies.

OphthalmologyNeurodegeneration

Technology Platform

DARC (Detection of Apoptosing Retinal Cells): A biomarker platform combining a patented fluorescent Annexin-based biologic that binds to externalized phosphatidylserine on stressed/apoptosing cells with an AI algorithm to analyze standard retinal images for cellular-level disease activity.

Opportunities

DARC addresses a major unmet need for early, objective biomarkers in neurodegenerative and ophthalmic diseases, enabling a shift from late-stage structural diagnosis to early detection of active cell stress.

The platform has a dual revenue potential: as a clinical diagnostic tool for ophthalmologists and as a companion biomarker for pharmaceutical companies to de-risk and accelerate neuroprotective drug development trials.

Risk Factors

Key risks include the clinical validation of DARC's utility and accuracy in larger trials, navigating the complex regulatory pathway for a novel diagnostic involving a biologic, and achieving commercial adoption against established standards of care.

As a pre-revenue company, it also faces execution and financing risks to reach key milestones.

Competitive Landscape

Novai operates in the emerging space of AI-enabled retinal diagnostics and biomarkers. While there are many companies developing AI for analyzing standard retinal images (e.g., for diabetic retinopathy), Novai's combination of a proprietary biologic with AI is highly differentiated. Potential competitors include other companies developing novel ophthalmic imaging agents or biomarkers for neurodegeneration, but DARC's specific mechanism targeting apoptosis appears unique in clinical development.

More companies in AI / Machine Learning →More companies in United Kingdom →